Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis

Clin Breast Cancer. 2016 Jun;16(3):e69-74. doi: 10.1016/j.clbc.2015.11.001. Epub 2015 Nov 17.
No abstract available

Keywords: Adjuvant; HER2+; Lapatinib; Rash; Toxicity.

Publication types

  • Case Reports
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Drug Eruptions* / epidemiology
  • Drug Eruptions* / pathology
  • Female
  • Humans
  • Lapatinib
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects
  • Trastuzumab / administration & dosage
  • Trastuzumab / adverse effects

Substances

  • Quinazolines
  • Lapatinib
  • Trastuzumab
  • Paclitaxel